Summary
The provided label excerpts only cover RA indication and selected warnings/precautions (serious infections, mortality, malignancy, MACE, thrombosis) and a dose interruption instruction. The AI statements include multiple claims (e.g., psoriatic arthritis and ulcerative colitis indications, manufacturing by Pfizer, typical methotrexate sequencing for each indication, specific side effects like headache/diarrhea/liver enzymes, and generic risk wording such as blood clots/stroke/heart attack/cancer) that are not supported by the supplied label excerpts and cannot be verified here; therefore label alignment cannot be confirmed.
Category Scores
Accurate Statements
Xeljanz is a Janus kinase (JAK) inhibitor medication.
Supported only insofar as the supplied label text refers to Janus kinase inhibitors (e.g., warnings about 'XELJANZ and other Janus kinase inhibitors'). The exact 'JAK inhibitor' phrasing is consistent with the excerpt context.
Xeljanz carries an increased risk of serious infections.
5.1 Serious Infections: 'at increased risk for developing serious... infections, including tuberculosis (TB)...'
Xeljanz has safety warnings that include risks of serious infections...
6.1 Clinical Trials Experience summary lists 'Serious Infections' and links to 5.1.
Xeljanz carries an increased risk of blood clots.
5.5 Thrombosis: 'Thrombosis, including pulmonary embolism, deep venous thrombosis, and arterial thrombosis...' (blood clots is a lay paraphrase of thrombosis).
Xeljanz carries an increased risk of stroke.
5.4 Major Adverse Cardiovascular Events: MACE includes 'cardiovascular death, myocardial infarction, and stroke.'
Xeljanz carries an increased risk of heart attack.
5.4 Major Adverse Cardiovascular Events: MACE includes 'myocardial infarction' (heart attack).
Xeljanz carries an increased risk of cancer.
5.3 Malignancy and Lymphoproliferative Disorders: 'Malignancies... have occurred...' and higher rate observed.
Unsupported Statements
Xeljanz is approved for the treatment of adults with active psoriatic arthritis.
Not supported by the supplied label excerpts (only RA indication excerpt is provided).
Xeljanz is approved for the treatment of adults with ulcerative colitis.
Not supported by the supplied label excerpts (only RA indication excerpt is provided).
Xeljanz is approved for the treatment of adults with moderate to severe active rheumatoid arthritis.
Supported generally by the supplied RA indication excerpt, but the AI phrasing differs ('inadequate response or intolerance to one or more TNF blockers' is not included in this statement). Without full label wording, only partial support can be confirmed; treated as unsupported/insufficiently precise.
For rheumatoid arthritis, Xeljanz is typically prescribed after an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs.
The supplied RA indication excerpt specifies inadequate response or intolerance to one or more TNF blockers, not methotrexate or other DMARDs.
For psoriatic arthritis, Xeljanz is typically prescribed after an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs.
Not supported because psoriatic arthritis indication is not provided in the excerpts; also the methotrexate sequencing conflicts with the RA TNF-blocker-based wording shown.
For ulcerative colitis, Xeljanz is used in adults with an inadequate response or loss of response to conventional therapy.
Not supported because ulcerative colitis indication language is not included in the supplied excerpts.
Xeljanz works by blocking the activity of Janus kinases (JAKs).
The excerpts mention 'Janus kinase inhibitors' and 'inflammatory conditions' but do not explicitly state 'blocking the activity of Janus kinases (JAKs)'.
JAKs are enzymes involved in signaling pathways that lead to inflammation.
Not stated in the provided label excerpts.
By inhibiting these pathways, Xeljanz helps to reduce inflammation.
Not stated in the provided label excerpts.
By inhibiting these pathways, Xeljanz helps to reduce symptoms associated with autoimmune diseases.
Not stated in the provided label excerpts.
Xeljanz is manufactured by Pfizer.
Not stated in the provided label excerpts.
Other potential side effects of Xeljanz may include upper respiratory tract infections.
The excerpts provided are warnings/precautions and adverse reaction headings only; no specific adverse event list for 'upper respiratory tract infections' is included.
Other potential side effects of Xeljanz may include headache.
Not stated in the provided label excerpts.
Other potential side effects of Xeljanz may include diarrhea.
Not stated in the provided label excerpts.
Other potential side effects of Xeljanz may include increased liver enzymes.
Not stated in the provided label excerpts.
The effectiveness and safety of Xeljanz have been demonstrated in multiple clinical trials across its approved indications.
No effectiveness or clinical trial summary text is included in the supplied excerpts.
The clinical trials evaluated Xeljanz's impact on disease activity.
No such clinical trial outcomes are included in the supplied excerpts.
The clinical trials evaluated Xeljanz's impact on patient-reported outcomes.
No such information is included in the supplied excerpts.
The clinical trials evaluated Xeljanz's safety events.
The excerpt only lists 'clinically significant adverse reactions' described elsewhere; no trial outcome description is provided.
Xeljanz belongs to a class of drugs known as JAK inhibitors.
While consistent with the term 'Janus kinase inhibitors' in the warnings, this specific classification statement is not explicitly provided in the excerpt sections.
Tofacitinib is the active ingredient in Xeljanz.
The prompt separately provides active ingredient(s), but it is not stated within the supplied label excerpts for validation; label excerpt compliance is not demonstrated.
Other JAK inhibitors include baricitinib.
Not stated in the provided label excerpts.
Other JAK inhibitors include upadacitinib.
Not stated in the provided label excerpts.
JAK inhibitors share a similar mechanism of action but may have different approved indications.
Not stated in the provided label excerpts.
JAK inhibitors share a similar mechanism of action but may have different safety profiles.
Not stated in the provided label excerpts.
JAK inhibitors share a similar mechanism of action but may have different dosing regimens.
Not stated in the provided label excerpts.
Patent disputes are common in the pharmaceutical market for JAK inhibitors.
Not part of prescribing information excerpts provided; not supported.
Litigation surrounding Xeljanz and other JAK inhibitors can impact market exclusivity.
Not part of prescribing information excerpts provided; not supported.
Litigation surrounding Xeljanz and other JAK inhibitors can impact the introduction of generic or biosimilar alternatives.
Not part of prescribing information excerpts provided; not supported.
Companies may challenge existing patents to open up pathways for their own products.
Not part of prescribing information excerpts provided; not supported.
Contradictions
Low
AI Statement
For rheumatoid arthritis, Xeljanz is typically prescribed after an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs.
Label Reference
1.1 Rheumatoid Arthritis: indicated for 'inadequate response or intolerance to one or more TNF blockers.'
Important Omissions
Specific TB testing and latent infection treatment prior to XELJANZ/XELJANZ XR initiation, as well as ongoing monitoring for TB during therapy.
Importance:
Moderate
Instruction to 'interrupt XELJANZ/XELJANZ XR if a patient develops a serious infection until the infection is controlled' (present in the label excerpts) was not stated in the provided AI list.
Importance:
Moderate
RA-specific risk framing in label: age 50+ with at least one cardiovascular risk factor; comparative study vs TNF blockers.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Although the AI correctly mentions several serious labeled safety themes (serious infections including TB, thrombosis, MACE components, malignancy), it also makes multiple unsupported/off-label/indication-expansion and nonspecific side-effect claims and omits key label-specific monitoring/interruption instructions; this reduces label fidelity but does not directly establish a single dangerous contraindicating error from the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple material claims (additional indications, sequencing/eligibility criteria, and specific side effects) are not supported by the supplied FDA label excerpts, and one eligibility/conditioning statement conflicts with the RA indication wording shown.
Suggested Improvement
Restrict claims to the provided label excerpts (RA indication based on TNF blockers; warnings: serious infections including TB with testing/monitoring; mortality; malignancy; MACE with RA 50+ CV risk factor; thrombosis and avoidance/discontinuation). Remove or clearly qualify unsupported indication, side-effect, and mechanistic statements not present in the provided label text.